Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy: Population-based Study
Eugenio Ventimiglia, Marcus Westerberg, Andri Wilberg Orasson, Mats Ahlberg, David Robinson, Rolf Gedeborg, Pär Stattin, Hans Garmo · 2026
Read Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy: Population-based Study by Eugenio Ventimiglia, Marcus Westerberg, Andri Wilberg Orasson, Mats Ahlberg, David Robinson, Rolf Gedeborg, Pär Stattin, Hans Garmo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13273858.txt.
Description
Ventimiglia and colleagues follow men whose PSA stayed stable on prostate drugs after a negative biopsy. Their 2026 journal article is a nationwide Swedish population study. PSA is a blood marker for prostate cancer.
The study used the PCBaSe Xtend database. It included 1,248 men who started 5-alpha reductase inhibitor therapy. These drugs shrink the prostate. Of the men, 901 had stable PSA and 347 had rising PSA. At ten years, cancer incidence was 8.3 percent with stable PSA. It was 18 percent with rising PSA. Most cancers in the stable group were low grade. Prostate cancer death was very low with stable PSA. The standardized mortality ratio there was 0.19. The authors say PSA trends could tailor follow-up intensity.
Catalog record
| CREATOR | Eugenio Ventimiglia, Marcus Westerberg, Andri Wilberg Orasson, Mats Ahlberg, David Robinson, Rolf Gedeborg, Pär Stattin, Hans Garmo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17490 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |